Abstract

Liver fibrosis is a common result of most chronic liver diseases, and advanced fibrosis often leads to cirrhosis. Currently, there is no effective treatment for liver cirrhosis except liver transplantation. Therefore, it is important to carry out antifibrosis treatment to reverse liver damage in the early stage of liver fibrosis. Mesenchymal stem cells (MSCs) are the most widely used stem cells in the field of regenerative medicine. The preclinical and clinical research results of MSCs in the treatment of liver fibrosis and cirrhosis show that MSC administration is a promising treatment for liver fibrosis and cirrhosis. MSCs reverse liver fibrosis and increase liver function mainly through differentiation into hepatocytes, immune regulation, secretion of cytokines and other nutritional factors, reduction of hepatocyte apoptosis, and promotion of hepatocyte regeneration. Recently, many studies provided a variety of new methods and strategies to improve the effect of MSCs in the treatment of liver fibrosis. In this review, we summarized the current effective methods and strategies and their potential mechanisms of MSCs in the treatment of liver fibrosis, as well as the current research progress in clinical practice. We expect to achieve complete reversal of liver injury with MSC-based therapy in the future.

Highlights

  • Liver fibrosis is a fibrotic and inflammatory process caused by chronic liver injury

  • Mesenchymal stem cells (MSCs) have the ability to differentiate into hepatocyte-like cells, many studies have shown that other effects of MSCs in treating liver fibrosis can be attributed to paracrine effects [95, 96]

  • Liver fibrosis is a pathophysiological process caused by various pathogenic factors and abnormal hyperplasia of connective tissue in liver

Read more

Summary

Introduction

Liver fibrosis is a fibrotic and inflammatory process caused by chronic liver injury. The most common pathogeneses are viral hepatitis infections (hepatitis B and C viral infections (HCV/HBV)), alcoholism, nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), and autoimmune hepatitis [2,3,4,5,6]. Their pathogenesis is different, their common endpoint is the development of liver cirrhosis. We summarize the current effective methods and potential mechanisms of MSCs treatment of liver fibrosis and discuss the current clinical trial process

Source of MSCs
The Applications of MSCs in the Treatment of Liver Fibrosis
Mechanisms of MSC-Based Therapy in Liver Fibrosis
Intravenous
Clinical Practice
Conclusion
Findings
Conflicts of Interest
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call